AVTX - CONSENSUS CO - Avalo Therapeutics, Inc

Avalo Therapeutics, Inc (AVTX) relies on early-stage immunological developments, which creates high risks due to the absence of stable sales. The operating model is based on outsourcing production and testing to minimize capital expenditures. The share price history, which currently stands at 45.01, is presented below. The company attracts leading scientists by offering R&D freedom and stock option programs to combat rare pathologies.

The stability of Avalo Therapeutics, Inc (AVTX) depends on the efficiency of managing external CRO and CMO contractors, which makes the business sensitive to outsourcing operational risks. The average analyst price target for the stock aggregates expert fair value estimates, allowing investors to compare the current quote with the expected growth potential and identify hidden market discounts.